ConductScience.org, home

Paper41848748

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Rowland T and 32 others. Clin Pharmacol Ther, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study. Papers, record 41848748. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41848748

Download JSON
Disease
COVID-19540 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
2026
PubMed
Publication types
Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Adaptive Clinical Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-08-13
PubMed

Authors33

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rowland TTimhttps://orcid.org/0000-0001-5059-065X
2FitzGerald RRichardhttps://orcid.org/0000-0003-0227-4200
3Challenger EElizabethhttps://orcid.org/0000-0002-8978-6067
4Dickinson LLaurahttps://orcid.org/0000-0001-5557-9396
5Else LJLaura Jhttps://orcid.org/0009-0007-0078-3294
6Walker LLaurenhttps://orcid.org/0000-0002-3827-4387
7Hale CColin
8Shaw VVictoriahttps://orcid.org/0000-0002-0429-0186
9Kelly CCallum
10Lyon RRebecca
11Gibney JJennifer
12Dhamani KKarim
13Irwin MMargaret
14Enever YYvanne
15Tetlow MMichellehttps://orcid.org/0000-0002-1064-3187
16Wood WWilliamhttps://orcid.org/0000-0003-0683-8085
17Reynolds HHelenhttps://orcid.org/0000-0001-7443-4520
18Chiong JJustinhttps://orcid.org/0000-0001-8063-6399
19Osanlou OOrodhttps://orcid.org/0000-0003-2921-0522
20Pertinez HHenryhttps://orcid.org/0009-0004-4522-9201

Source PubMed

See all 33 authorsDownload CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AmidesMajor topic
Antiviral AgentsMajor topic
COVID-19 Drug TreatmentMajor topic
PyrazinesMajor topic
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Administration, Intravenous
Bayes Theorem
COVID-19
Dose-Response Relationship, Drug
Hospitalization
SARS-CoV-2

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
75F40120C00085US Food and Drug AdministrationPubMed
NIHR300576National Institute for Health and Care ResearchPubMed
National Institute for Health Research Southampton Biomedical Research CentrePubMed
MR/V028391/1Medical Research CouncilUnited KingdomPubMed
MR/W005611/1Medical Research CouncilUnited KingdomPubMed
MC_UU_00040/03Medical Research CouncilUnited KingdomPubMed
221590/Z/20/ZWellcome TrustUnited KingdomPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04746183AGILE (Early Phase Platform Trial for COVID-19)Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128231247Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.PLoS Negl Trop Dis2017https://conductscience.org/library/papers/28231247PubMed
230951731Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir).Antiviral Res2019https://conductscience.org/library/papers/30951731PubMed
332438446Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.Clin Pharmacol Ther2020https://conductscience.org/library/papers/32438446PubMed
427736754Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/27736754PubMed
532350860Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2.Clin Pharmacol Ther2020https://conductscience.org/library/papers/32350860PubMed
639397762A seamless Phase I/II platform design with a time-to-event efficacy endpoint for potential COVID-19 therapies.Stat Methods Med Res2024https://conductscience.org/library/papers/39397762PubMed
734450619Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.J Antimicrob Chemother2021https://conductscience.org/library/papers/34450619PubMed
833091434Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.Antiviral Res2020https://conductscience.org/library/papers/33091434PubMed
932679055In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.Antiviral Res2020https://conductscience.org/library/papers/32679055PubMed
1026930627Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.PLoS Med2016https://conductscience.org/library/papers/26930627PubMed
1133741945Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.Nat Commun2021https://conductscience.org/library/papers/33741945PubMed
1235639525Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials.J Infect Dis2022https://conductscience.org/library/papers/35639525PubMed
1332943628Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.Nat Commun2020https://conductscience.org/library/papers/32943628PubMed
1431207186Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages.CPT Pharmacometrics Syst Pharmacol2019https://conductscience.org/library/papers/31207186PubMed
1532251767Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.Antiviral Res2020https://conductscience.org/library/papers/32251767PubMed
1632366720Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/32366720PubMed
1732020029Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.Cell Res2020https://conductscience.org/library/papers/32020029PubMed
1832246834Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.Clin Pharmacol Ther2020https://conductscience.org/library/papers/32246834PubMed
1937739792Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza.J Infect Dis2024https://conductscience.org/library/papers/37739792PubMed
2032475019Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.Clin Transl Sci2020https://conductscience.org/library/papers/32475019PubMed

See all 36 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42479031Pharmacokinetics of injectable favipiravir: phase I, randomized, double-blind, placebo-controlled study in healthy East Asian subjects.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/42479031PubMed
42396859Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.J Antimicrob Chemother2026https://conductscience.org/library/papers/42396859PubMed
42141199Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial.Nat Med2026https://conductscience.org/library/papers/42141199PubMed

Download CSV of cited by

Drugs6

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
NITAZOXANIDECHEMBL1401Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1401ChEMBL
FAVIPIRAVIRCHEMBL221722Derived from the trial1https://conductscience.org/library/drugs/CHEMBL221722ChEMBL
REMDESIVIRCHEMBL4065616Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4065616ChEMBL
MOLNUPIRAVIRCHEMBL4650320Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4650320ChEMBL
SOTROVIMABCHEMBL4650524Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4650524ChEMBL
BELUDAVIMABCHEMBL4802220Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4802220ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41848748

GET https://conductscience.org/api/papers/v1/41848748/authors?page=2